Welcome to our dedicated page for SANGAMO THERAPEUTICS news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on SANGAMO THERAPEUTICS stock.
Sangamo Therapeutics reports developments in genomic medicine, with a pipeline centered on neurological diseases, Fabry disease gene therapy, zinc finger epigenetic regulation, capsid discovery and modular integrase technology. Company updates commonly cover clinical and nonclinical data presentations, regulatory submissions for isaralgagene civaparvovec, or ST-920, in Fabry disease, and neurology programs such as small fiber neuropathy and chronic neuropathic pain.
Recurring news also includes financial results, earnings calls, collaboration and licensing activity around neurotropic capsids, and public-company matters affecting SGMO common stock. Listing-status announcements, including Nasdaq compliance and OTCQB quotation matters, form part of the company's corporate-status coverage alongside pipeline and technology updates.
Sangamo Therapeutics (Nasdaq: SGMO) announced positive topline results from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The study demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 patients, which will serve as the primary basis for FDA approval.
Key highlights include maintained elevated α-Gal A activity for up to 4.5 years, successful withdrawal of all 18 patients from enzyme replacement therapy (ERT), and significant improvements in quality of life scores. The therapy showed a favorable safety profile without preconditioning requirements. Sangamo plans to submit a Biologics License Application (BLA) in Q1 2026 under the Accelerated Approval pathway.
Sangamo Therapeutics (NASDAQ: SGMO) has announced a change in timing for its first quarter 2025 earnings call. The call has been rescheduled from 4:30 p.m. Eastern to 6:30 p.m. Eastern on Monday, May 12, 2025. The registration and access details remain unchanged, with participants able to join via the same previously provided link.
Attendees are encouraged to join 10 minutes before the start time and can choose between dialing in with a provided number and passcode or using a dial-out option. The webcast will be available through the Investors and Media section of Sangamo's website, with a replay accessible after the call.
Sangamo Therapeutics (NASDAQ: SGMO), a genomic medicine company, has scheduled its first quarter 2025 financial results release for Monday, May 12, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern the same day to discuss financial results and provide business updates.
Participants can register and access the call through a provided link, with a recommendation to join 10 minutes before the start. They can either dial in with a unique passcode or use the dial-out option. A webcast will be available on Sangamo's website in the Investors and Media section, with a replay accessible afterward.
Sangamo Therapeutics (NASDAQ: SGMO) has achieved key milestones for its Fabry disease gene therapy candidate ST-920 (isaralgagene civaparvovec). All patients in the Phase 1/2 STAAR study have completed the FDA-required 52-week follow-up for Accelerated Approval pathway. Preliminary analysis across 32 dosed patients shows continued positive mean eGFR slope, with the therapy being well-tolerated. A productive Type B CMC meeting with the FDA has provided a clear pathway to the planned BLA submission in Q1 2026.
The company expects a pivotal data readout by end of Q2 2025, with potential approval and commercial launch as early as H2 2026. Sangamo is currently in discussions with EMA regarding potential European approval and engaging in business development negotiations for Fabry commercialization.
Summary not available.
Sangamo Therapeutics (SGMO) has entered into a license agreement with Eli Lilly for its proprietary neurotropic AAV capsid, STAC-BBB, which demonstrates strong blood-brain barrier penetration capabilities. The agreement includes:
- An $18 million upfront license fee
- Potential earnings of up to $1.4 billion in additional fees and milestone payments across five possible disease targets
- Tiered royalties on potential net sales
Lilly receives worldwide exclusive rights to use STAC-BBB for one initial target, with the option to add four additional targets for treating central nervous system diseases. This marks Sangamo's third agreement since announcing STAC-BBB in March 2024. Sangamo will handle the technology transfer, while Lilly will be responsible for research, development, manufacturing, and commercialization of resulting gene therapy products.
Sangamo Therapeutics (NASDAQ: SGMO) reported key developments and financial results for Q4 and full year 2024. The company secured two significant neurology license agreements: a global epigenetic regulation and capsid delivery agreement with Genentech and a capsid license agreement with Astellas, raising over $100M in non-dilutive funding.
Key highlights include: FDA clearance for ST-503 IND for treating intractable pain, with patient enrollment expected mid-2025; successful nonclinical proof of concept in prion disease; and alignment with FDA on Accelerated Approval pathway for isaralgagene civaparvovec in Fabry disease.
Financial results show Q4 2024 net loss of $23.4M ($0.11/share) compared to $60.3M loss in Q4 2023. Full-year 2024 net loss was $97.9M versus $257.8M in 2023. Q4 revenues were $7.6M, up from $2.0M in Q4 2023. Cash position stood at $41.9M as of December 31, 2024.
Sangamo Therapeutics (SGMO) has scheduled its fourth quarter and full year 2024 financial results release for Monday, March 17, 2025, after market close. The company will host an earnings conference call at 4:30 p.m. Eastern on the same day.
Additionally, Sangamo announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, Florida, from March 11-13, 2025. CEO Sandy Macrae will present on Wednesday, March 12 at 12:00 p.m. Eastern. Both the earnings call and conference presentation will be accessible via webcast, with replays available afterward.